George Sakoulas, MD
Infectious Disease · San Diego, CANPI 1184647893
Payments from drug & device makers
Across 1,308 payments — averaging $1126.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$587K
- Octapharma USA, Inc.$571K
- Paratek Pharmaceuticals, Inc.$224K
- Aimmune Therapeutics, Inc.$34K
- La Jolla Pharmaceutical Company$15K
- Melinta Therapeutics, LLC$13K
- plus $30K from 14 others
Across 4 payments — averaging $5512.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Octapharma USA, Inc.$22K
What the payments were for
- Consulting fees$25,8703%
- Speaking & faculty fees$705,74678%
- Travel & lodging$151,61217%
- Food & beverage$18,7712%
- Education$2930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 857 | $587,062 |
| Octapharma USA, Inc. | 9 | $571,014 |
| Paratek Pharmaceuticals, Inc. | 325 | $223,683 |
| Aimmune Therapeutics, Inc. | 28 | $33,538 |
| La Jolla Pharmaceutical Company | 18 | $15,070 |
| Melinta Therapeutics, LLC | 26 | $13,099 |
| Shionogi Inc | 14 | $9,260 |
| Biomerieux Inc | 2 | $6,160 |
| Gilead | 3 | $3,936 |
| Xellia Pharmaceuticals | 6 | $3,326 |
| Ferring Pharmaceuticals Inc. | 1 | $2,760 |
| Tetraphase Pharmaceuticals, Inc. | 4 | $1,887 |
| Sobi, Inc | 1 | $1,500 |
| Veloxis Pharmaceuticals, Inc. | 2 | $250 |
| Astellas Pharma US Inc | 2 | $177 |
| GSK | 1 | $98 |
| Insmed, Inc. | 4 | $71 |
| Merck | 3 | $39 |
| Janssen Products, LP | 1 | $31 |
| Theratechnologies Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,472,982 in reported general payments places this provider in the 95th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 22 | $19,694 |
| ErtapenemErtapenem Sodium | 22 | $5,323 |
| Meropenem | 15 | $5,260 |
| Itraconazole | 14 | $4,986 |
| Azithromycin | 66 | $3,577 |
| CeftriaxoneCeftriaxone Sodium | 31 | $2,865 |
| MicafunginMicafungin Sodium | 11 | $2,088 |
| Fluconazole | 20 | $1,871 |
| Ampicillin Sodium | 17 | $1,579 |
| Cefazolin Sodium | 29 | $1,481 |
| Doxycycline Monohydrate | 15 | $1,419 |
| Minocycline Hcl | 53 | $1,334 |
| Doxycycline Hyclate | 26 | $1,176 |
| Ethambutol Hcl | 12 | $687 |
| Cephalexin | 17 | $518 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in San Diego
- David PrideSan Diego$2.8M
- Theodoros KatsivasSan Diego$1.1M
- Timothy WilkinSan Diego$1.1M
- David LooneySan Diego$675K
- Eliah Aronoff-SpencerSan Diego$351K
- Hai ShaoSan Diego$327K
- Peter RuaneLos Angeles$24.6M
- Raphael LandovitzLos Angeles$21.4M
- Philip RobinsonNewport Beach$4.9M
- Shawn HasslerSan Francisco$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.